Cannabis Use and its Medical Risks and Benefits: Leveraging Mobile Technology and Consumer Genomics

摘要 R21项目实施了一项创新的在线/移动的招聘和评估战略，并将其应用于 确定影响大麻使用的遗传因素以及相关的医疗风险和益处。经常，招聘 并且为人类遗传学研究开发足够大的群体是缓慢和昂贵的。我们 这种方法将通过招募已经进行基因分型的消费者基因组学客户来大大减少时间和成本 并通过移动的设备和互联网以电子方式评估他们的物质使用情况。拟议的工作建立 我们的成瘾基因组学（GENA）移动的应用程序原型在2016年NIDA中获得三等奖 挑战“成瘾研究：有一个应用程序”（https：www.drugabuse.gov/researchers/research- 资源/NIDA-挑战-程序）。具体来说，为了确定涉及大麻使用和相关医疗的位点， 风险和收益，我们将：（1）完成并实施我们的“直接面向参与者”接口， 参与者使用我们的移动的应用程序和网站提供知情同意，大麻使用的答案 问题，并安全访问其现有的全基因组基因型数据;（2）招募和电子 评估大麻使用性状的全基因组关联研究（GWAS）的一个大型，动力良好的队列 （3）分析我们新的GWAS队列，以确定与医学相关的基因座。 大麻使用特征和使用频率的量化。我们新颖的，直接对参与者的协议将立即 处理高度优先的物质大麻，并建立一个应对新出现的研究的平台 物质使用领域的需求。

ABSTRACT This R21 project implements an innovative online/mobile recruitment and assessment strategy and applies it to identify genetic factors that influence cannabis use and related medical risks and benefits. Too often, recruiting and developing sufficiently large cohorts for human genetic studies has been slow and expensive. Our approach will greatly reduce time and costs by recruiting already-genotyped consumer genomics customers and electronically assessing their substance use via mobile devices and the internet. The proposed work builds on our prototype Genomics of Addiction (GENA) mobile app that earned third prize in the 2016 NIDA Challenge “Addiction Research: There's an App for That” (https://www.drugabuse.gov/researchers/research- resources/nida-challenges-program). Specifically, to identify loci involved in cannabis use and related medical risks and benefits, we will: (1) Finalize and implement our “direct-to-participant” interface, which allows participants to use our mobile app and website to provide informed consent, answers to cannabis use questions, and secure access to their existing genome-wide genotype data; (2) Recruit and electronically assess a large, well-powered cohort for a genome-wide association study (GWAS) of cannabis use traits important to public health; (3) Analyze our new GWAS cohort to identify loci associated with medically relevant cannabis use traits and quantitative frequency of use. Our novel, direct-to-participant protocol will immediately address a high-priority substance, cannabis, and establish a platform for responding to emerging research needs in the substance use field.